Octreotide Acetate Injection

DESCRIPTION

Octreotide acetate injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

The octreotide acetate content was 91.0% (free peptide, C₃₅H₅₇N₁₀O₁₄S₂) and the amino acid sequence is:

H-Phe-pro-oxy-oxy-oxy-oxy-oxy-pro-Tyr-Thr-Val-Asn-Glu-Leu-Glu
with a molecular weight of 1280 Da (free peptide).

Octreotide Acetate Injection, a cyclic octapeptide prepared as a sterile, single-use, lyophilized powder, contains 50 mg (1 mL) of octreotide acetate. Each mL of the multi-dose vial also contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
- 2 mg of sodium hydroxide,
- 2 mg of sodium hydrogen carbonate,
- 0.1 mg of sodium fluoride,
- 0.1 mg of sodium azide,
- 0.02 mg of benzyl alcohol.

Each mL of the multi-dose vial contains:

- sodium chloride,
- 7 mg of sodium acetate,
- 5 mg of sodium dihydrogen phosphate,
Gallbladder Abnormalities

Acromegaly:
- It is not known whether octreotide is excreted into human milk. If octreotide acetate is used in a nursing mother, the benefit of continued breastfeeding should be carefully weighed against the potential for adverse events in the nursing infant.

Secondary Adverse Events

ADVERSE REACTIONS

The following adverse reactions have been identified during clinical trials using octreotide acetate:
- Hypoglycemia
- Hyperglycemia
- Hypothyroidism
- IGF-I (somatomedin C) levels increase and signs and symptoms of acromegaly improve significantly in patients on long-term therapy. For approximately 2% of patients.

Hypoglycemia

If overdose occurs, symptomatic management is indicated.

- In adults, the doses ranged from 250 to 6,000 micrograms/day administered by intermittent IM injections at weekly intervals. In a single randomized, double-blind, placebo-controlled, six-week study of 81 patients with acromegaly, the mean dosage was approximately 450 mcg, but clinical effectiveness. Doses greater than 300 mcg/day seldom result in increased therapeutic response, but usually doses above 450 mcg/day are not required.

Hypothyroidism

Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection.

- In acromegalic patients, IGF-I (somatomedin C) levels increase, and signs and symptoms of acromegaly improve, but usually doses above 450 mcg/day are not required. The highest recommended human dose based on body surface area was 750 mcg/day. Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Diarrhea occurred in 11 of 30 (37%) patients treated with octreotide acetate for injectable suspension. No unexpected adverse events were observed. However, with octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- In acromegalic patients, biochemical hypothyroidism alone occurred in 12% while growth occurred in 6% during octreotide acetate therapy (see PREDICTIONS). In patients treated with octreotide acetate, hypothyroidism has only been reported in several unusual case reports.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection. Acromegalic patients, sinus bradycardia (<50 bpm) developed in 10% and biochemical hypothyroidism occurred in 15% of patients.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection. Acromegalic patients, sinus bradycardia (<50 bpm) developed in 10% and biochemical hypothyroidism occurred in 15% of patients.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection. Acromegalic patients, sinus bradycardia (<50 bpm) developed in 10% and biochemical hypothyroidism occurred in 15% of patients.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection. Acromegalic patients, sinus bradycardia (<50 bpm) developed in 10% and biochemical hypothyroidism occurred in 15% of patients.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.

- Gelatin, borax, polysorbate 80, hydroxypropyl methylcellulose, and lactose are the only ingredients in octreotide acetate (120,000 mcg) (base) given intravenously over 8 hours to patients with acromegaly who have not been previously treated with octreotide acetate injection. Acromegalic patients, sinus bradycardia (<50 bpm) developed in 10% and biochemical hypothyroidism occurred in 15% of patients.

- Adverse Events

- Vomiting, flatulence, and abnormal studies although only 2.6% of the patients discontinued acetate therapy (see.

- Anaphylactoid reactions, including anaphylactic shock, have been reported. If symptoms of anaphylaxis (e.g., tightness of the chest, wheezing, laryngospasm, shock) occur, the solution should be discontinued.

- Significant renal dysfunction (creatinine clearance of 15 mL/min or less) is a contraindication for octreotide acetate use in children, most notably in children with cystic fibrosis. Pediatric patients should be closely monitored for clinical signs of fluid retention or congestive heart failure.